Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RAD51B
Variant R8*
Impact List nonsense
Protein Effect loss of function - predicted
Gene Variant Descriptions RAD51B R8* results in a premature truncation of the Rad51b protein at aa 8 of 384 (UniProt.org). R8* has not been characterized, however, due to the effects of truncation mutations downstream of R8 (PMID: 9788630), is predicted to lead to a loss of Rad51b protein function.
Associated Drug Resistance
Category Variants Paths

RAD51B mutant RAD51B inact mut RAD51B R8*

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_133510.4
gDNA chr14:g.67823565C>T
cDNA c.22C>T
Protein p.R8*
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001321819.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321818.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321809 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321818.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133509 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321809.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321821 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
XM_011537051 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
XM_017021545.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_002877 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321818 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133509.3 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321812.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133510.4 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321819 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321814.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321819.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133510.3 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321812.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321821.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321810.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321809.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321821.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321814 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
XM_011537050.3 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
XM_011537050 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
XM_017021545 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_002877.6 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321812 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133510 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321814.2 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_133509.5 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321810 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_001321810.1 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38
NM_002877.5 chr14:g.67823565C>T c.22C>T p.R8* RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RAD51B inact mut prostate cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in guidelines as second-line therapy post androgen receptor-directed therapy for patients with metastatic castration-resistant prostate cancer harboring pathogenic mutations in RAD51B (NCCN.org). detail...
RAD51B inact mut prostate cancer sensitive Olaparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) treatment significantly improved median imaging-based progression-free survival (5.8 vs 3.5 mo, HR 0.49, p<0.001) compared to control in patients with metastatic castration-resistant prostate cancer who progressed on hormone therapy and harbored deleterious or suspected deleterious mutations in homologous recombination repair genes, including RAD51B (PMID: 32343890; NCT02987543). detail... detail... 32343890
RAD51B mutant ovary serous adenocarcinoma predicted - sensitive Cediranib + Olaparib Clinical Study - Cohort Actionable In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in heavily pretreated high-grade serous ovarian cancer patients (n=34), and a median PFS of 4.8 months in patients (n=14) harboring mutations in either BRCA1, BRCA2, or RAD51B (PMID: 32444417; NCT02681237). 32444417